Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Drug-Coated Balloons Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The drug-coated balloons market has shown substantial growth in recent years. This market is expected to expand from $1.24 billion in 2025 to $1.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.5%. Historically, this growth has been driven by the increasing prevalence of cardiovascular diseases, the expansion of interventional cardiology procedures, the early adoption of paclitaxel-coated balloons, a growing demand for restenosis prevention, and advancements in angioplasty techniques.
The drug-coated balloons market size is anticipated to experience substantial growth over the upcoming years. It is projected to reach $2.55 billion in 2030 at a compound annual growth rate (CAGR) of 15.6%. This expansion during the forecast period is primarily driven by the escalating use of dcb therapies in coronary applications, the increasing embrace of next-generation coating technologies, the broadening scope of catheter-based interventions, rising investments in vascular innovation, and a growing preference for stent-free treatment options. Significant trends expected in this period include the increased adoption of sirolimus-coated balloons, a rising deployment of dcbs in peripheral artery disease, a growing inclination towards minimally invasive vascular treatments, the proliferation of advanced drug-coating technologies, and a strengthened focus on improving drug delivery efficiency.
Get A Free Sample Report With In-Depth Market Insights:
Drug-Coated Balloons Market Demand Drivers: What’s Powering Industry Growth?
The increasing number of ambulatory surgery centers is projected to boost the growth of the drug-coated balloon market moving forward. An Ambulatory Surgical Center (ASC) is defined as a medical facility solely for conducting surgical procedures that do not necessitate an overnight hospital stay. Drug-coated balloons are crucial in ambulatory surgery centers (ASC) due to their typically shorter procedure times compared to standard balloons, which results in improved patient throughput and reduced operational costs in ASCs. For example, in March 2025, the Medicare Payment Advisory Commission (an independent U.S. federal advisory agency) reported that from 2022 through 2023, the count of Medicare-certified ASCs rose by 2.5% to 6,308 ASCs, indicating a net gain of 155 facilities during 2023. Consequently, the expansion in the number of ambulatory surgery centers is propelling the growth of the drug-coated balloon market.
Drug-Coated Balloons Market Segmentation: How Does The Market Break Down By Category?
The drug-coated balloons market covered in this report is segmented –
1) By Product: Drug-Coated Balloons For Peripheral Artery Disease, Drug-Coated Balloons For Coronary Artery Disease
2) By Drug Type: Paclitaxel, Sirolimus
3) By End User: Hospitals, Cardiac Catheterization Labs, Ambulatory Surgical Centers
Subsegments:
1) By Drug-Coated Balloons For Peripheral Artery Disease: Paclitaxel-Coated Balloons, Sirolimus-Coated Balloons
2) By Drug-Coated Balloons For Coronary Artery Disease: Paclitaxel-Coated Balloons, Sirolimus-Coated Balloons
Drug-Coated Balloons Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies engaged in drug-coated balloons are dedicated to advancing their technologies, such as paclitaxel-coated balloon catheters, with the aim of improving treatment efficacy for conditions like coronary in-stent restenosis, enhancing patient outcomes, and reducing the risks of complications associated with traditional therapies. Paclitaxel-coated balloon catheters are devices engineered to release the drug paclitaxel into the artery wall when inflated, thereby helping to prevent re-narrowing following angioplasty. For instance, in March 2024, Boston Scientific Corporation, a US-based medical device company, obtained US Food and Drug Administration (FDA) approval for its AGENTTM Drug-Coated Balloon (DCB). This device is intended for the management of coronary in-stent restenosis (ISR) in patients with coronary artery disease, which occurs when a stented blood vessel becomes blocked or narrowed due to plaque or scar tissue.
Drug-Coated Balloons Market Key Participants And Competitive Landscape
Major companies operating in the drug-coated balloons market are Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Biosensors International Group Ltd, Concept Medical Inc., Acotec Scientific AG, Cardionovum GmbH, MedAlliance SA, iVascular SLU, Minvasys SAS, QT Vascular Ltd, Hexacath SAS, Cordis Corporation, MicroPort Scientific Corporation, Endocor GmbH, Orchestra BioMed Inc., Lepu Medical Technology Co. Ltd, Balton Sp. z o.o., BrosMed Medical Co. Ltd
View The Full Drug-Coated Balloons Market Report:
Drug-Coated Balloons Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the global drug-coated balloons market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug-coated balloons market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
